217 related articles for article (PubMed ID: 35218499)
1. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
Delgado N; Torres A
Curr Oncol Rep; 2022 May; 24(5):645-650. PubMed ID: 35218499
[TBL] [Abstract][Full Text] [Related]
2. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Başcı S; Ata N; Altuntaş F; Yiğenoğlu TN; Dal MS; Korkmaz S; Namdaroğlu S; Baştürk A; Hacıbekiroğlu T; Doğu MH; Berber İ; Dal K; Erkurt MA; Turgut B; Çağlayan M; Ayvalı MO; Çelik O; Ülgü MM; Birinci Ş;
J Oncol Pharm Pract; 2020 Oct; 26(7):1676-1682. PubMed ID: 32854573
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in persons with chronic myeloid leukaemia.
Li W; Wang D; Guo J; Yuan G; Yang Z; Gale RP; You Y; Chen Z; Chen S; Wan C; Zhu X; Chang W; Sheng L; Cheng H; Zhang Y; Li Q; Qin J; ; Meng L; Jiang Q
Leukemia; 2020 Jul; 34(7):1799-1804. PubMed ID: 32424293
[TBL] [Abstract][Full Text] [Related]
4. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
Bonifacio M; Tiribelli M; Miggiano MC; Abruzzese E; Binotto G; Scaffidi L; Cordioli M; Damiani D; Di Bona E; Trawinska MM; Tanasi I; Dubbini MV; Velotta V; Ceccarelli G; Pierdomenico E; Lo Schirico M; Semenzato G; Ruggeri M; Fanin R; Tacconelli E; Pizzolo G; Krampera M
Cancer Med; 2021 Sep; 10(18):6310-6316. PubMed ID: 34464516
[TBL] [Abstract][Full Text] [Related]
5. Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review.
Asif M; Amir M; Hussain A; Achakzai NM; Natesan Pushparaj P; Rasool M
Medicine (Baltimore); 2022 Jul; 101(26):e29660. PubMed ID: 35777011
[TBL] [Abstract][Full Text] [Related]
6. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Cakir B
J Oncol Pharm Pract; 2020 Dec; 26(8):2068-2069. PubMed ID: 33081582
[No Abstract] [Full Text] [Related]
7. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
8. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
Qi F; Bao M; Gao H; Zhang X; Zhao S; Wang C; Li W; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2707-2716. PubMed ID: 37578540
[TBL] [Abstract][Full Text] [Related]
9. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review.
Harjianti T; Benyamin F; Minhajat R; Saleh S; Bayu D; Pababbari W
Acta Med Indones; 2023 Jul; 55(3):332-338. PubMed ID: 37915153
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Fu J; Liu Y; Lin H; Wu B
Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
[TBL] [Abstract][Full Text] [Related]
13. Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization.
Civettini I; Antolini L; Brioschi F; Zambrotta GPM; Guglielmana V; Gambacorti-Passerini C
Cancer Med; 2023 Apr; 12(8):9662-9667. PubMed ID: 37039261
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 and chronic myeloid leukemia: a systematic review.
Ali EA; Al-Sadi A; Al-Maharmeh Q; Subahi EA; Bellamkonda A; Kalavar M; Panigrahi K; Alshurafa A; Yassin MA
Front Med (Lausanne); 2023; 10():1280271. PubMed ID: 38327268
[TBL] [Abstract][Full Text] [Related]
16. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
17. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Breccia M; Abruzzese E; Accurso V; Attolico I; Barulli S; Bergamaschi M; Binotto G; Bocchia M; Bonifacio M; Caocci G; Capodanno I; Castagnetti F; Cavazzini F; Crisà E; Crugnola M; Stella De Candia M; Elena C; Fava C; Galimberti S; Gozzini A; Gugliotta G; Intermesoli T; Iurlo A; La Barba G; Latagliata R; Leonetti Crescenzi S; Levato L; Loglisci G; Lucchesi A; Luciano L; Lunghi F; Luzi D; Malato A; Cristina Miggiano M; Pizzuti M; Pregno P; Rapezzi D; Rege-Cambrin G; Rosti G; Russo S; Sancetta R; Rita Scortechini A; Sorà F; Sportoletti P; Stagno F; Tafuri A; Tiribelli M; Foà R; Saglio G
Br J Haematol; 2022 Feb; 196(3):559-565. PubMed ID: 34636033
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
20. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.
Graf I; Herndlhofer S; Kundi M; Greiner G; Sperr M; Hadzijusufovic E; Valent P; Sperr WR
Eur J Haematol; 2023 Jan; 110(1):67-76. PubMed ID: 36193973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
